The molecular docking results revealed that ICA exhibited binding activity to the corresponding targets of AD, suggesting its potential to act on AD-related targets and exert therapeutic effects through the HIF-1, MAPK, mTOR, and P13K-Akt pathways. Here, MTOR is linked to Alzheimer disease.